Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis
Completed
Biogen
Phase 3
2009-06-01
The primary objective of this study is to determine the efficacy of peginterferon beta-1a in
reducing the annualized relapse rate (ARR) in participants with relapsing multiple sclerosis
(RMS) at 1 year. The secondary objectives of this study are to determine whether
peginterferon beta-1a, at 1 year when compared with placebo, is effective in reducing the
total number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance
imaging (MRI) scans, reducing the proportion of participants who relapse, and slowing the
progression of disability.
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
Completed
Biogen
Phase 3
2011-04-01
The primary objective of this study is to evaluate the long-term safety and tolerability of
peginterferon beta-1a (BIIB017) in participants originally treated in Study 105MS301
(NCT00906399) who continue peginterferon beta-1a treatment. The secondary objective of this
study is to describe long-term multiple sclerosis (MS) outcomes in participants originally
treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment.
The primary objective of the study is to prospectively evaluate pregnancy outcomes in women
with multiple sclerosis who were exposed to a Registry-specified Biogen Multiple Sclerosis
product during the eligibility window for that product. The Registry-specified Biogen MS
products being studied are dimethyl fumarate, and Pegylated human interferon beta-1a. The
secondary objective of the study is to prospectively evaluate pregnancy outcomes in women
with MS who were unexposed to disease-modifying therapies (DMTs).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
